Mar 22nd 2013 - Edison Investment Research today published a report on quickview entitled "Little Margin For Risk". In summary, the report says: Mesoblast is an ASX-listed biotechnology company with a large R&D pipeline built on a proprietary stem cell technology.
http://www.stockopedia.co.uk/research/little-margin-for-risk-71867/
http://www.stockopedia.co.uk/research/little-margin-for-risk-71867/
No comments:
Post a Comment